ECSP099600A - Co-cristales y composicón farmaceútica de los mismos - Google Patents

Co-cristales y composicón farmaceútica de los mismos

Info

Publication number
ECSP099600A
ECSP099600A EC2009009600A ECSP099600A ECSP099600A EC SP099600 A ECSP099600 A EC SP099600A EC 2009009600 A EC2009009600 A EC 2009009600A EC SP099600 A ECSP099600 A EC SP099600A EC SP099600 A ECSP099600 A EC SP099600A
Authority
EC
Ecuador
Prior art keywords
crystals
same
pharmaceutical composition
inhibitor
hepatitis
Prior art date
Application number
EC2009009600A
Other languages
English (en)
Inventor
Patrick R Connelly
Irina Kidiyala
Kathy Stavropolus
Yuegang Zhang
Steve Johnston
Govinda Rao Bhisetti
Valdas Jurkauskas
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of ECSP099600A publication Critical patent/ECSP099600A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención se refiere a composiciones que contienen un inhibidor (VX-950) de la hepatitis C y un específico co-cristal. Este inhibidor que tiene la estructura que se muestra a continuación es un compuesto que es muy necesitado para inhibir la hepatitis C.
EC2009009600A 2007-02-27 2009-08-27 Co-cristales y composicón farmaceútica de los mismos ECSP099600A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90358707P 2007-02-27 2007-02-27

Publications (1)

Publication Number Publication Date
ECSP099600A true ECSP099600A (es) 2009-09-29

Family

ID=39672669

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009600A ECSP099600A (es) 2007-02-27 2009-08-27 Co-cristales y composicón farmaceútica de los mismos

Country Status (28)

Country Link
US (1) US8759353B2 (es)
EP (3) EP2463285A1 (es)
JP (1) JP2010519330A (es)
KR (1) KR20090115970A (es)
CN (1) CN101687856A (es)
AP (1) AP2009004960A0 (es)
AR (1) AR065498A1 (es)
AT (1) ATE542815T1 (es)
AU (1) AU2008219607B2 (es)
BR (1) BRPI0807907A2 (es)
CA (1) CA2679312A1 (es)
CO (1) CO6220963A2 (es)
CY (1) CY1112865T1 (es)
DK (1) DK2114924T3 (es)
EA (1) EA200970806A1 (es)
EC (1) ECSP099600A (es)
ES (1) ES2379905T3 (es)
GE (1) GEP20125645B (es)
HR (1) HRP20120330T1 (es)
IL (1) IL200616A0 (es)
MX (1) MX2009009182A (es)
NZ (1) NZ579442A (es)
PL (1) PL2114924T3 (es)
PT (1) PT2114924E (es)
RS (1) RS52306B (es)
SI (1) SI2114924T1 (es)
TW (1) TW200846343A (es)
WO (1) WO2008106151A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
CA2643688A1 (en) * 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
AU2009288200A1 (en) * 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
EP2396028A2 (en) 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
WO2011054741A2 (en) * 2009-11-06 2011-05-12 Basf Se Crystalline complexes of 4-hydroxy benzoic acid and selected pesticides
TW201130502A (en) 2010-01-29 2011-09-16 Vertex Pharma Therapies for treating hepatitis C virus infection
WO2011112922A2 (en) * 2010-03-11 2011-09-15 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
WO2012009503A1 (en) 2010-07-14 2012-01-19 Vertex Pharmaceuticals Incorporated Palatable pharmaceutical composition comprising vx-950
US20140308242A1 (en) 2010-10-21 2014-10-16 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
FR2976284B1 (fr) * 2011-06-09 2013-05-24 Servier Lab Nouveaux co-cristaux d'agomelatine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
WO2013116339A1 (en) 2012-01-31 2013-08-08 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
WO2014015217A1 (en) 2012-07-19 2014-01-23 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
WO2014033617A1 (en) * 2012-08-31 2014-03-06 Novartis Ag 2'-ethynyl nucleoside derivatives for treatment of viral infections
ITMI20131839A1 (it) * 2013-11-06 2015-05-07 Dipharma Francis Srl Co-cristallo di un farmaco antidepressivo
CN103819379A (zh) * 2014-02-18 2014-05-28 中国科学院上海药物研究所 维生素d3的胆甾烷醇共结晶及其制备方法和应用
CN105696066B (zh) * 2015-10-26 2018-07-03 西北大学 一种压片法制备共晶的方法
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CN113295723B (zh) * 2021-07-27 2021-09-28 西南石油大学 一种岩石中粘土矿物的分子模拟表征方法

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3226768A1 (de) 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
DE3211676A1 (de) 1982-03-30 1983-10-06 Hoechst Ag Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5496927A (en) 1985-02-04 1996-03-05 Merrell Pharmaceuticals Inc. Peptidase inhibitors
EP0204571B1 (en) 1985-06-07 1992-01-22 Ici Americas Inc. Selected difluoro derivatives
US5231084A (en) * 1986-03-27 1993-07-27 Hoechst Aktiengesellschaft Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons
US5736520A (en) * 1988-10-07 1998-04-07 Merrell Pharmaceuticals Inc. Peptidase inhibitors
NZ235155A (en) 1989-09-11 1993-04-28 Merrell Dow Pharma Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical
US5371072A (en) 1992-10-16 1994-12-06 Corvas International, Inc. Asp-Pro-Arg α-keto-amide enzyme inhibitors
EP0604182B1 (en) * 1992-12-22 2000-10-11 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of Aids
KR100187990B1 (ko) 1992-12-29 1999-06-01 스티븐 에프. 웨인스톡 레트로바이러스성 프로테아제 억제 화합물 제조용 합성 중간체
US5384410A (en) * 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
US5656600A (en) 1993-03-25 1997-08-12 Corvas International, Inc. α-ketoamide derivatives as inhibitors of thrombosis
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5468858A (en) 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
HUT72440A (en) 1994-03-31 1996-04-29 Bristol Myers Squibb Co Imidazole-containing inhibitors of farnesyl protein transferase and pharmaceutical compositions containing them
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
JP2000500760A (ja) * 1995-11-23 2000-01-25 メルク シヤープ エンド ドーム リミテツド スピロピペリジン誘導体およびタキキニン拮抗薬としてのその使用
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
ZA972195B (en) * 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
TR199802136T2 (xx) * 1996-04-23 2001-06-21 Vertex Pharmaceuticals Incorporated �MPDH enzimi inhibit�rleri olarak �re t�revleri.
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
US6153579A (en) 1996-09-12 2000-11-28 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
US6046195A (en) * 1996-09-25 2000-04-04 Merck Sharp & Dohme Ltd. Spiro-azacyclic derivatives, their preparation and their use as tachykinin antagonists
JP2001502316A (ja) * 1996-10-08 2001-02-20 コロラド ステート ユニバーシティ リサーチ ファンデーション 触媒不斉エポキシ化
CZ298749B6 (cs) * 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
GB9623908D0 (en) * 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
DE19648011A1 (de) * 1996-11-20 1998-05-28 Bayer Ag Cyclische Imine
ATE244717T1 (de) * 1997-03-14 2003-07-15 Vertex Pharma Inhibitoren des impdh-enzyms
GB9708484D0 (en) * 1997-04-25 1997-06-18 Merck Sharp & Dohme Therapeutic agents
GB9711114D0 (en) * 1997-05-29 1997-07-23 Merck Sharp & Dohme Therapeutic agents
WO1999007734A2 (en) 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
US6767991B1 (en) * 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
US6183121B1 (en) * 1997-08-14 2001-02-06 Vertex Pharmaceuticals Inc. Hepatitis C virus helicase crystals and coordinates that define helicase binding pockets
US20040058982A1 (en) * 1999-02-17 2004-03-25 Bioavailability System, Llc Pharmaceutical compositions
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
WO1999028482A2 (en) 1997-11-28 1999-06-10 Schering Corporation Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide
EP1066247B1 (en) * 1998-03-31 2006-11-22 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US6251583B1 (en) * 1998-04-27 2001-06-26 Schering Corporation Peptide substrates for HCV NS3 protease assays
GB9812523D0 (en) * 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
DE19836514A1 (de) * 1998-08-12 2000-02-17 Univ Stuttgart Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette
US6117639A (en) 1998-08-31 2000-09-12 Vertex Pharmaceuticals Incorporated Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity
US6025516A (en) * 1998-10-14 2000-02-15 Chiragene, Inc. Resolution of 2-hydroxy-3-amino-3-phenylpropionamide and its conversion to C-13 sidechain of taxanes
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
US20020042046A1 (en) * 1999-02-25 2002-04-11 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
ES2405316T3 (es) 1999-03-19 2013-05-30 Vertex Pharmaceuticals Incorporated Inhibidores de la enzima IMPDH
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US7122627B2 (en) * 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
US20020183249A1 (en) 1999-08-31 2002-12-05 Taylor Neil R. Method of identifying inhibitors of CDC25
CA2390349A1 (en) 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
EP1261611A2 (en) * 2000-02-29 2002-12-04 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
DE60111509T2 (de) 2000-04-03 2006-05-11 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von Serin-Proteasen, insbesondere der Hepatitis-C-Virus NS23-Protease
JP4748911B2 (ja) * 2000-04-05 2011-08-17 シェーリング コーポレイション Ｎ−環状ｐ２部分を含むｃ型肝炎ウイルスの大環状ｎｓ３‐セリンプロテアーゼ阻害剤
CN1432022A (zh) * 2000-04-19 2003-07-23 先灵公司 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3－丝氨酸蛋白酶抑制剂
US7419678B2 (en) 2000-05-12 2008-09-02 Cordis Corporation Coated medical devices for the prevention and treatment of vascular disease
EP2289888A3 (en) 2000-06-30 2011-07-13 Seikagaku Corporation Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them
RU2003105221A (ru) 2000-07-21 2004-09-20 Шеринг Корпорейшн (US) Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита с
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US20020068702A1 (en) * 2000-07-21 2002-06-06 Marguerita Lim-Wilby Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
CZ303213B6 (cs) * 2000-07-21 2012-05-23 Schering Corporation Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostredek
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
AR034127A1 (es) * 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
US6777400B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6846806B2 (en) * 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
CA2429359A1 (en) * 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
CN1301994C (zh) * 2000-12-12 2007-02-28 先灵公司 作为c型肝炎病毒ns3－丝氨酸蛋白酶抑制剂的二芳基肽
US6727366B2 (en) * 2000-12-13 2004-04-27 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
US6653295B2 (en) * 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
DZ3487A1 (fr) * 2001-01-22 2002-07-25 Merck Sharp & Dohme Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US20020187488A1 (en) 2001-01-30 2002-12-12 Chao Lin Quantitative assay for nucleic acids
JP4499990B2 (ja) 2001-03-27 2010-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Ｈｃｖ感染に有用な組成物および方法
GB0107924D0 (en) * 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
JP4455056B2 (ja) * 2001-07-11 2010-04-21 バーテックス ファーマシューティカルズ インコーポレイテッド 架橋二環式セリンプロテアーゼ阻害剤
JP2003055389A (ja) 2001-08-09 2003-02-26 Univ Tokyo 錯体及びそれを用いたエポキシドの製法
US6824769B2 (en) 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
US20030229390A1 (en) 2001-09-17 2003-12-11 Control Delivery Systems, Inc. On-stent delivery of pyrimidines and purine analogs
EP1441720B8 (en) * 2001-10-24 2012-03-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
MXPA04004657A (es) * 2001-11-14 2004-08-13 Teva Pharma Formas amorfas y cristalinas de potasio de losartan y proceso para su preparacion.
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
IL163846A0 (en) * 2002-03-01 2005-12-18 Univ South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
NZ575692A (en) * 2002-04-11 2009-10-30 Vertex Pharma Inhibitors of Serine Proteases, Particularly Hepatitis C Virus NS3-NS4 Protease
US20030204168A1 (en) 2002-04-30 2003-10-30 Gjalt Bosma Coated vascular devices
US6835387B2 (en) 2002-06-11 2004-12-28 Scimed Life Systems, Inc. Sustained release of superoxide dismutase mimics from implantable or insertable medical devices
SG174624A1 (en) * 2002-08-01 2011-10-28 Pharmasset Inc Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
JP4027751B2 (ja) 2002-08-23 2007-12-26 横浜ゴム株式会社 タイヤ用ホイールセット及びそれを装着した車両
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US6715452B1 (en) 2002-11-13 2004-04-06 Arvin Technologies, Inc. Method and apparatus for shutting down a fuel reformer
CA2413705A1 (en) * 2002-12-06 2004-06-06 Raul Altman Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
CA2514092C (en) * 2003-01-21 2013-03-19 S.S.C.I., Inc. Novel cocrystallization of hydrochloric acid salt of an active agent
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
BRPI0407587A (pt) 2003-02-18 2006-02-14 Pfizer inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam
AU2003272270A1 (en) * 2003-02-28 2004-09-28 The Regents Of The University Of Michigan Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP4682140B2 (ja) 2003-03-05 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類縁体
EP1601685A1 (en) 2003-03-05 2005-12-07 Boehringer Ingelheim International GmbH Hepatitis c inhibiting compounds
CN100453553C (zh) * 2003-04-11 2009-01-21 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
CA2522577C (en) * 2003-05-21 2011-04-26 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
CA2532664A1 (en) 2003-07-18 2005-01-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
TW201127828A (en) * 2003-09-05 2011-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7365092B2 (en) * 2003-10-10 2008-04-29 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
AU2004282148A1 (en) 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incoporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
JP2007509950A (ja) * 2003-10-27 2007-04-19 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｈｃｖ処置の組合せ剤
WO2005043118A2 (en) * 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
WO2005042570A1 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Hcv ns3-ns4a protease resistance mutants
ATE442355T1 (de) 2003-10-28 2009-09-15 Vertex Pharma Herstellung von 4,5-dialkyl-3-acylpyrrol-2- carbonsäurederivaten durch synthese nach fischer- fink und anschliebende acylierung
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1689857A1 (en) 2003-12-01 2006-08-16 Vertex Pharmaceuticals Incorporated Compositions comprising fetal liver cells and methods useful for hcv infection
CA2549851C (en) 2004-01-21 2012-09-11 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
EP1711515A2 (en) 2004-02-04 2006-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
TWI368507B (en) 2004-02-20 2012-07-21 Boehringer Ingelheim Int Viral polymerase inhibitors
US20050187192A1 (en) 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
ES2328589T3 (es) 2004-02-27 2009-11-16 Schering Corporation Compuestos de la prolina 3,4(ciclopentil) fusionados como inhibidores de la proteasa serina ns3 del virus de la hepatitis c.
CN102225936B (zh) * 2004-03-12 2013-09-11 弗特克斯药品有限公司 制备化合物的方法
PE20060309A1 (es) 2004-05-06 2006-04-13 Schering Corp (1r,2s,5s)-n-[(1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2s)-2[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.o]hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de l
RU2373923C2 (ru) * 2004-06-08 2009-11-27 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтические композиции
JP5017103B2 (ja) * 2004-06-17 2012-09-05 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 薬剤共結晶組成物および関連した使用方法
EP1797111B1 (en) * 2004-08-27 2011-06-22 Schering Corporation Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease
RU2007116265A (ru) 2004-10-01 2008-11-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибирование протеазы ns3-ns4a вируса hcv
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
US7863274B2 (en) 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
CN101277950B (zh) * 2005-08-02 2013-03-27 弗特克斯药品有限公司 丝氨酸蛋白酶抑制剂
SG2014013338A (en) * 2005-08-19 2014-06-27 Vertex Pharma Processes and intermediates
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
CA2643688A1 (en) * 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
EP1993993A1 (en) 2006-03-16 2008-11-26 Vertex Pharmaceuticals Incorporated Processes and intermediates for preparing steric compounds
US20070225297A1 (en) 2006-03-16 2007-09-27 Perni Robert B Deuterated hepatitis C protease inhibitors
US20070218138A1 (en) 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
EA018811B1 (ru) 2006-03-20 2013-10-30 Вертекс Фармасьютикалз Инкорпорейтед Способы получения твердой дисперсии лекарственного средства и твердые дисперсии лекарственного средства, полученные этим способом
PL2037887T3 (pl) * 2006-05-31 2011-03-31 Vertex Pharma Doustne preparaty o kontrolowanym uwalnianiu inhibitora enzymu konwertującego interleukinę 1 beta

Also Published As

Publication number Publication date
SI2114924T1 (sl) 2012-06-29
BRPI0807907A2 (pt) 2017-05-16
WO2008106151A3 (en) 2008-11-06
IL200616A0 (en) 2010-05-17
AU2008219607A1 (en) 2008-09-04
KR20090115970A (ko) 2009-11-10
CO6220963A2 (es) 2010-11-19
ATE542815T1 (de) 2012-02-15
NZ579442A (en) 2012-02-24
AR065498A1 (es) 2009-06-10
CY1112865T1 (el) 2016-04-13
AP2009004960A0 (en) 2009-08-31
US20110059987A1 (en) 2011-03-10
DK2114924T3 (da) 2012-04-10
WO2008106151A2 (en) 2008-09-04
EA200970806A1 (ru) 2010-08-30
ES2379905T3 (es) 2012-05-04
CA2679312A1 (en) 2008-09-04
EP2463285A1 (en) 2012-06-13
TW200846343A (en) 2008-12-01
EP2114924B1 (en) 2012-01-25
JP2010519330A (ja) 2010-06-03
RS52306B (sr) 2012-12-31
MX2009009182A (es) 2009-09-04
AU2008219607B2 (en) 2013-09-12
US8759353B2 (en) 2014-06-24
PT2114924E (pt) 2012-04-03
HRP20120330T1 (hr) 2012-05-31
EP2114924A2 (en) 2009-11-11
GEP20125645B (en) 2012-09-25
EP2463284A1 (en) 2012-06-13
CN101687856A (zh) 2010-03-31
PL2114924T3 (pl) 2012-07-31

Similar Documents

Publication Publication Date Title
ECSP099600A (es) Co-cristales y composicón farmaceútica de los mismos
UY31260A1 (es) Compuestos de pirazol, composiciones conteniendolos y aplicaciones.
BR122019015876B8 (pt) compostos derivados de 1,2,5-oxadiazóis, composição, bem como seus usos
CU23783B7 (es) Compuestos de 4-metil piridopirimidinona
GT200600341A (es) Inhibidores macrociclicos del virus de la hepatitis c
CU20200051A7 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
CL2008003690A1 (es) Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos.
UY29266A1 (es) Compuestos de piridazinona
UY31906A (es) Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias.
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
GT201200230A (es) Inhibidores del virus de la hepatitis c
HN2008000134A (es) Inhibidores macrociclicos del virus hepatitis c
ECSP13012540A (es) Compuestos y composiciones novedosos para la inhibición de nampt
UY35300A (es) Formulación de combinación de dos compuestos antivirales
CR11316A (es) Derivado de uracilo o timina para el tratamiiento de la hepatitis c.
CY1112102T1 (el) Υποκατεστημενες πυριμιδοδιαζεπινες χρησιμες ως αναστολεις plk1
BR122018001898B8 (pt) Composição para controlar pragas invertebradas e composição
BR112013005108A2 (pt) compostos e composições de guanidina para a inibição de nampt
PA8827001A1 (es) Derivados de indazol sustituidos con fenilo y benzodioxinilo
AR062211A1 (es) Derivados de 6-carboxi-normorfinano. composiciones farmaceuticas
ATE542798T1 (de) Organische verbindungen
UY30787A1 (es) "inhibidores benzoimidazolicos de trpv1"
UY31134A1 (es) Derivados de piperidina/piperazina (i)
UY29360A1 (es) Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones.
CO6351777A2 (es) Compuestos de tetraciclina sustituidod con fluor en c7